A fixed-dose combination pill developed by Gilead Sciences has successfully met its primary endpoint in a Phase 3 clinical trial. The ARTISTRY-2 trial results indicate that...
ViiV Healthcare has announced that its long-acting HIV pre-exposure prophylaxis (PrEP) therapy, cabotegravir, demonstrated superior acceptability among patients compared to Gilead Sciences‘ lenacapavir in an early-stage...
